- Home
- CRNX vs SRAD Comparison
CRNX vs SRAD Comparison
Compare CRNX & SRAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRNX | SRAD |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.3B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRNX | SRAD |
|---|---|---|
| Price | $83.98 | $12.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | ★ $76.75 | $24.31 |
| AVG Volume (30 Days) | ★ 6.8M | 2.4M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $720.10 | $24.03 |
| Revenue Next Year | $184.67 | $14.81 |
| P/E Ratio | ★ N/A | $49.48 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $11.55 |
| 52 Week High | $84.00 | $32.22 |
Technical Indicators
Market Signals| Indicator | CRNX | SRAD |
|---|---|---|
| Relative Strength Index (RSI) | 90.37 | N/A |
| Support Level | $43.40 | N/A |
| Resistance Level | $84.00 | N/A |
| Average True Range (ATR) | 0.19 | 0.00 |
| MACD | -1.64 | 0.00 |
| Stochastic Oscillator | 71.70 | 0.00 |
Price Performance
Historical ComparisonAbout CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
About SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.